SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company’s quality control process. Sensors identified

Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients MUMBAI, India and PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, (together with its subsidiaries and/or affiliated companies,

Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer Early MCED prospective data show low anxiety and minimal psychological burden in real-world use ABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care

VIENNA, May 26, 2026 /PRNewswire/ -- A new episode of Beyond Biotech podcast, produced by Labiotech, is now live, featuring Dr. Stéphane Barges, CEO of Lexogen, alongside Dr. Quin Wills, Founder and CEO of Ochre Bio. In this episode, Lexogen's CEO shares his perspective on the growing role of RNA sequencing and transcriptomics in enabling AI-driven drug discovery. The discussion highlights how high-quality, dedicated data built with AI training in mind is becoming essential to improve relevant t

Collaborative research on AI-based diagnosis of multiple sclerosis, Building a clinical trial dataset Leveraging large-scale, multi-center brain MRI datasets to detect key lesion biomarkers SEOUL, South Korea, May 26, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it will conduct a joint research collaboration with the Vall d'Hebron Institut de Recerc

AUSTIN, May 26, 2026 /PRNewswire/ -- TOBY, Inc., a biotechnology company developing non-invasive disease detection technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the TOBY Test for Alzheimer's Disease. The designation recognizes the test's potential to aid in the diagnosis of Alzheimer's disease through a simple, non-invasive urine sample and address a major unmet need in accessible cognitive evaluation and diagnostic

Hepcludex ® is a first-in-class entry inhibitor approved for the treatment of adults with chronic hepatitis delta (HDV) infection. ELK GROVE VILLAGE, Ill., May 26, 2026 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, announced today that it is the contracted specialty pharmacy for Gilead's Hepcludex® (bulevirtide‑gmod) 8.5 mg, a subcutaneous injection for the treatment of chronic hepatitis delta (HDV) infection in adults without cirrhosis or with compensated cirrhosis, which

TORONTO, May 26, 2026 /PRNewswire/ - Apotex Inc. ("Apotex" or the "Company"), the largest Canadian‑based pharmaceutical company, today announced that Health Canada has approved IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel 3%), a topical ophthalmic anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures in adults.[1] With approval granted, IHEEZO™ will be available to Canadian healthcare professionals as a sterile, preservative‑free gel formulation supplied in

ZHUBEI, May 26, 2026 /PRNewswire/ -- Precision and minimally invasive are more than technical goals—they are a pledge to uphold patient dignity. In the high-stakes realm of neurosurgery, where the brain's complexity leaves only a millimeter of room for error, the demand for perfection is redefining the future of medical innovation. Continue Reading Prof. Dr. med. Ehab Shiban uses NaoTrac for brain surgery navigation. Tracing the history of neurosurgery, traditional stereotactic surgery opened th

Repository standardizes how biological assays are captured, shared, and reused Zifo worked collaboratively with regulatory authorities and Pistoia Alliance members Steering committee included representatives from AbbVie, Novartis, Merck and Roche CAMBRIDGE, Mass. and CAMBRIDGE, England, May 26, 2026 /PRNewswire/ -- Zifo, the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, is proud to announce the successful development and launch of the In